Medscape Neurology

🧠 Rethinking what’s possible in Parkinson disease. Explore the limitations of current PD therapies and early cell-based approaches—and dive into the mechanisms behind emerging cell therapies shaping the future of care. 🔬 Get the latest on ongoing clinical trials and what they mean for practice. 📍 Click here now: mdsc.pe/4aY17uE

🧠 What does FcRn blockade mean for the future of MG care? 💻 Dive into the latest efficacy and safety data for FcRn inhibitors and 📖 learn how antibody-depleting therapies are transforming treatment strategies. 🔗 events.medscapelive.org/website/93628/

🧠 Rethinking what’s possible in Parkinson disease. Explore the limitations of current PD therapies and early cell-based approaches—and dive into the mechanisms behind emerging cell therapies shaping the future of care. 🔬 Get the latest on ongoing clinical trials and what they mean for practice. 📍 Click here now: mdsc.pe/4aY17uE

🧠 Rethinking what’s possible in Parkinson disease. Explore the limitations of current PD therapies and early cell-based approaches—and dive into the mechanisms behind emerging cell therapies shaping the future of care. 🔬 Get the latest on ongoing clinical trials and what they mean for practice. 📍 Click here now: mdsc.pe/4aY17uE

🧠 What does FcRn blockade mean for the future of MG care? 💻 Dive into the latest efficacy and safety data for FcRn inhibitors and 📖 learn how antibody-depleting therapies are transforming treatment strategies. 🔗 events.medscapelive.org/website/93628/

🧠 Rethinking what’s possible in Parkinson disease. Explore the limitations of current PD therapies and early cell-based approaches—and dive into the mechanisms behind emerging cell therapies shaping the future of care. 🔬 Get the latest on ongoing clinical trials and what they mean for practice. 📍 Click here now: mdsc.pe/4aY17uE

From GI symptoms and scoliosis to epilepsy and autonomic dysfunction, Rett syndrome demands a team-based approach. See why a multi-disciplinary team is essential for navigating the complex needs of these patients as they age ➡️ x.com/i/broadcasts/1… #Neurology #RareDisease #CME

From scraping the internet for answers to curated Medscape content you can trust. Discover trusted medical intelligence with Medscape AI: medscape.com/ai-search?quer…

📊 Why do many patients with myasthenia gravis continue to struggle—even on treatment? Join this session for real patient experience with emerging clinical evidence to uncover the true burden of MG across the lifespan. 🔍 Secure your spot now: mdsc.pe/4r5WPXP

🩺 Myasthenia Gravis isn’t always controlled—even on therapy. Learn about ongoing symptom burden, lifelong challenges, and the clinical rationale for targeted treatment strategies. Learn more by clicking here: mdsc.pe/4r5WPXP

💥 Myasthenia gravis doesn’t end with treatment. From mental well-being to social exhaustion, patients face challenges that often go unseen. Hear a patient’s story and explore why new MG therapies are urgently needed. 🚀 Register now: mdsc.pe/4r5WPXP

📊 Why do many patients with myasthenia gravis continue to struggle—even on treatment? Join this session for real patient experience with emerging clinical evidence to uncover the true burden of MG across the lifespan. 🔍 Secure your spot now: mdsc.pe/4r5WPXP

💥 Myasthenia gravis doesn’t end with treatment. From mental well-being to social exhaustion, patients face challenges that often go unseen. Hear a patient’s story and explore why new MG therapies are urgently needed. 🚀 Register now: mdsc.pe/4r5WPXP

🧠 Rethinking what’s possible in Parkinson disease. Explore the limitations of current PD therapies and early cell-based approaches—and dive into the mechanisms behind emerging cell therapies shaping the future of care. 🔬 Get the latest on ongoing clinical trials and what they mean for practice. 📍 Click here now: mdsc.pe/4aY17uE

The diagnostic odyssey for rare diseases is too long. As a contributor to the latest @wef rare disease whitepaper, we highlight that education makes a difference and drives measurable change to shorten the diagnostic odyssey - mdsc.pe/4qYFU8S

Are you familiar with the first and only FDA-approved treatment for Rett syndrome? Learn about its clinical impact, including real-world behavioral and communication improvements seen in both pediatric and adult patients. Watch the full video ➡️ x.com/i/broadcasts/1… #Neurology #RareDisease #CME

Earlier diagnosis can lead to better treatment options and outcomes. This year for #RareDiseaseDay 2026 we stand with Medics for Rare Disease in their mission to #LearnYourStripes. We’re helping HCPs build confidence in recognising and supporting patients with rare conditions. Explore the training video and campaign assets here: mdsc.pe/4tQP5Ln Be #RareAware on 28 Feb and #ShowYourStripes!

Evidence-based answers in seconds, powered by trusted Medscape content. Try Medscape AI today: medscape.com/ai-search?quer…

🩺 Myasthenia Gravis isn’t always controlled—even on therapy. Learn about ongoing symptom burden, lifelong challenges, and the clinical rationale for targeted treatment strategies. Learn more by clicking here: mdsc.pe/4r5WPXP

Migraine care is evolving. In this CME, experts break down who qualifies for preventive therapy and how to select an evidence-based first-line option for patients with frequent migraine.. Learn more: bit.ly/45Jt4nl